NeuroOne Medical Technologies Corp (NASDAQ: NMTC)’s stock price has soared by 7.55 in relation to previous closing price of 0.60. Nevertheless, the company has seen a gain of 11.84% in its stock price over the last five trading days. globenewswire.com reported 2025-06-03 that EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary.
Is It Worth Investing in NeuroOne Medical Technologies Corp (NASDAQ: NMTC) Right Now?
Additionally, the 36-month beta value for NMTC is 0.72. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NMTC is 43.85M and currently, short sellers hold a 0.45% ratio of that float. The average trading volume of NMTC on June 18, 2025 was 297.40K shares.
NMTC’s Market Performance
NMTC’s stock has seen a 11.84% increase for the week, with a -2.27% drop in the past month and a -35.65% fall in the past quarter. The volatility ratio for the week is 4.60%, and the volatility levels for the past 30 days are at 4.16% for NeuroOne Medical Technologies Corp The simple moving average for the past 20 days is 8.26% for NMTC’s stock, with a -22.83% simple moving average for the past 200 days.
Analysts’ Opinion of NMTC
Many brokerage firms have already submitted their reports for NMTC stocks, with Ladenburg Thalmann repeating the rating for NMTC by listing it as a “Buy.” The predicted price for NMTC in the upcoming period, according to Ladenburg Thalmann is $1.45 based on the research report published on May 05, 2025 of the current year 2025.
Craig Hallum, on the other hand, stated in their research note that they expect to see NMTC reach a price target of $2, previously predicting the price at $6. The rating they have provided for NMTC stocks is “Hold” according to the report published on March 29th, 2022.
NMTC Trading at 9.89% from the 50-Day Moving Average
After a stumble in the market that brought NMTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.24% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NMTC starting from Christianson Mark, who sale 10,000 shares at the price of $0.58 back on Jun 04 ’25. After this action, Christianson Mark now owns 261,491 shares of NeuroOne Medical Technologies Corp, valued at $5,804 using the latest closing price.
Christianson Mark, the Business Development Director of NeuroOne Medical Technologies Corp, sale 8,967 shares at $0.62 during a trade that took place back on May 22 ’25, which means that Christianson Mark is holding 271,491 shares at $5,586 based on the most recent closing price.
Stock Fundamentals for NMTC
Current profitability levels for the company are sitting at:
- -1.14 for the present operating margin
- 0.54 for the gross margin
The net margin for NeuroOne Medical Technologies Corp stands at -1.15. The total capital return value is set at -2.44. Equity return is now at value -265.18, with -134.06 for asset returns.
Based on NeuroOne Medical Technologies Corp (NMTC), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -15.66. The debt to equity ratio resting at 0.28. The interest coverage ratio of the stock is -20.26.
Currently, EBITDA for the company is -11.84 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 5.45. The receivables turnover for the company is 18.07for trailing twelve months and the total asset turnover is 1.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.09.
Conclusion
In conclusion, NeuroOne Medical Technologies Corp (NMTC) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
